Advertisement

CNS Drugs

, Volume 32, Issue 10, pp 951–961 | Cite as

Palliative Sedation for the Terminally Ill Patient

  • Ferdinando Garetto
  • Ferdinando Cancelli
  • Romina Rossi
  • Marco Maltoni
Review Article
  • 165 Downloads

Abstract

Palliative sedation (PS) is performed in the terminally ill patient to manage one or more refractory symptoms. Proportional PS, which means that drugs can be titrated to the minimum effective dose, is the form most widely used. From a quarter to a third of all terminally ill patients undergo PS, with a quarter of these requiring continuous deep sedation. The prevalence of PS varies according to the care setting and case mix. The most frequent refractory physical symptoms are delirium and dyspnea, but PS is also considered for existential suffering or psychological distress, which is an extremely difficult and delicate issue to deal with. Active consensus from the patient and advanced care planning is recommended for PS. The decision-making process concerning the continuation or withdrawal of other treatments is not the same as that used for PS. The practice differs totally from euthanasia in its intentions, procedures, and results. The most widely used drugs are midazolam and haloperidol for refractory delirium, but chlorpromazine and other neuroleptics are also effective. In conclusion, some patients experience refractory symptoms during the last hours or days of life and PS is a medical intervention aimed at managing this unbearable suffering. It does not have a detrimental effect on survival.

Notes

Acknowledgements

The authors thank Gráinne Tierney for editorial assistance.

Compliance with Ethical Standards

Funding

No sources of funding were used in the preparation of this paper.

Conflict of interest

Ferdinando Garetto, Ferdinando Cancelli, Romina Rossi and Marco Maltoni have no conflicts of interest to declare for this paper.

Ethical approval and informed consent

Given the nature of this paper, ethical approval and informed consent were not required.

References

  1. 1.
    Byock I. Palliative care and the right to die. In: The 2015 Quality of death index. Ranking palliative care across the world. The Economist Intelligence Unit. 2018. https://www.eiuperspectives.economist.com/sites/default/files/2015%20EIU%20Quality%20of%20Death%20Index%20Oct%2029%20FINAL.pdf. Accessed 19 May 2018.
  2. 2.
    Juth N, Lindblad A, Lynöe N, Sjöstrand M, Helgesson GM. Differences in deep continuous palliative sedation and euthanasia. BMJ Support Palliat Care. 2013;3:203–6.PubMedGoogle Scholar
  3. 3.
    Miccinesi G, Caraceni A, Maltoni M. Palliative sedation: ethicalaspects. Minerva Anestesiol. 2017;83:1317–23.PubMedGoogle Scholar
  4. 4.
    Cherny NI, Radbruch L. Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23:581–93.PubMedGoogle Scholar
  5. 5.
    Schildmann E, Schildmann J. Palliative sedation therapy: a systematic literature review and critical appraisal of available guidance on indication and decision making. J Palliat Med. 2014;17:601–11.PubMedGoogle Scholar
  6. 6.
    Maltoni M, Scarpi E, Nanni O. Palliative sedation for intolerable suffering. Curr Opin Oncol. 2014;26:389–94.PubMedGoogle Scholar
  7. 7.
    Cotogni P, Brazzi L. Palliative sedation: a feasible option to improve end-of-life care in seriously ill dying patients. Minerva Anestesiol. 2017;83:446–8.PubMedGoogle Scholar
  8. 8.
    Abarshi E, Rietjens J, Robijn L, Caraceni A, Payne S, Deliens L, et al. International variations in clinical practice guidelines for palliative sedation: a systematic review. BMJ Support Palliat Care. 2017;7:223–9.PubMedGoogle Scholar
  9. 9.
    Maltoni M, Scarpi E, Rosati M, Derni S, Fabbri L, Martini F, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol. 2012;30:1378–83.PubMedGoogle Scholar
  10. 10.
    Schur S, Weixler D, Gabl C, Kreye G, Likar R, Masel EK, et al. AUPACS (Austrian Palliative Care Study) Group. Sedation at the end of life - a nation-wide study in palliative care units in Austria. BMC Palliat Care. 2016;14(15):50.Google Scholar
  11. 11.
    Azoulay D, Shahal-Gassner R, Yehezkel M, Eliyahu E, Weigert N, Ein-Mor E, et al. Palliative sedation at the end of life: patterns of use in an israeli hospice. Am J Hosp Palliat Care. 2016;33:369–73.PubMedGoogle Scholar
  12. 12.
    Hamano J, Morita T, Ikenaga M, Abo H, Kizawa Y, Tunetou S. A nationwide survey about palliative sedation involving Japanese palliative care specialists: Intentions and key factors used to determine sedation as proportionally appropriate. J Pain Symptom Manage. 2018;55:785–91.PubMedGoogle Scholar
  13. 13.
    Bush SH, Grassau PA, Yarmo MN, Zhang T, Zinkie SJ, Pereira JL. The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice. BMC Palliative Care. 2014;13:17.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O’Neal PV, Keane KA, et al. The Richmond Agitation Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166:1338–44.PubMedGoogle Scholar
  15. 15.
    Arevalo JJ, Brinkkemper T, van der Heide A, Rietjens JA, Ribbe M, Deliens L, et al. AMROSE Site Study Group. Palliative sedation: reliability and validity of sedation scales. J Pain Symptom Manage. 2012;44:704–14.PubMedGoogle Scholar
  16. 16.
    Gélinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15:420–7.PubMedGoogle Scholar
  17. 17.
    Rudkin GE, Osborne GA, Curtis NJ. Intra-opertaivepatient-controlledsedation. Anesthesia. 1991;46:90–2.Google Scholar
  18. 18.
    Masman AD, van Dijk M, van Rosmalen J, van Oud-Alblas HJ, Ista E, Baar FP, Tibboel D. Bispectral index monitoring in terminally ill patients: a validation study. J Pain Symptom Manage. 2016;52:212–20.PubMedGoogle Scholar
  19. 19.
    Barbato M, Barclay G, Potter J, Yeo W, Chung J. Correlation between observational scales of sedation and comfort and Bispectral Index Scores (BIS). J Pain Symptom Manage. 2017;54:186–93.PubMedGoogle Scholar
  20. 20.
    Schildmann EK, Schildmann J, Kiesewetter I. Medication and monitoring in palliative sedation therapy: a systematic review and quality assessment of published guidelines. J Pain Symptom Manage. 2015;49:734–46.PubMedGoogle Scholar
  21. 21.
    Maltoni M, Pittureri C, Scarpi E, Piccinini L, Martini F, Turci P, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol. 2009;20:1163–9.PubMedGoogle Scholar
  22. 22.
    Maltoni M, Miccinesi G, Morino P, Scarpi E, Bulli F, Martini F, et al. Prospective observational italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care. Support Care Cancer. 2012;20:2829–36.PubMedGoogle Scholar
  23. 23.
    Caraceni A, Zecca E, Martini C, Gorni G, Campa T, Brunelli C, et al. Palliative sedation at the end of life at a tertiary cancer center. Support Care Cancer. 2012;20:1299–307.PubMedGoogle Scholar
  24. 24.
    Mercadante S, Porzio G, Valle A, Fusco F, Aielli F, Adile C, et al. Home Care-Italy Group (HOCAI)Palliative sedation in advanced cancer patients followed at home: a retrospective analysis. J Pain Symptom Manage. 2012;43:1126–30.PubMedGoogle Scholar
  25. 25.
    Claessens P, Menten J, Schotsmans P, Broeckaert B. Level of consciousnessin dying patients. The role of palliative sedation: a longitudinal prospectivestudy. Am J HospPalliat Care. 2012;29:195–200.Google Scholar
  26. 26.
    Chambaere K, Bilsen J, Cohen J, Rietjens JA, Onwuteaka-Philipsen BD, Mortier F, et al. Continuous deep sedation until death in Belgium: a nationwide survey. Arch Intern Med. 2010;170:490–3.PubMedGoogle Scholar
  27. 27.
    Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care. 1994;10:31–8.PubMedGoogle Scholar
  28. 28.
    Bush SH, Tierney S, Lawlor PG. Clinical assessment and management of delirium in the palliative care setting. Drugs. 2017;77:1623–43.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Campbell ML, Kiernan JM, Strandmark J, Yarandi HN. trajectory of dyspnea and respiratory distress among patients in the last month of life. J Palliat Med. 2018;21:194–9.PubMedGoogle Scholar
  30. 30.
    Rodrigues P, Crokaert J, Gastmans C. Palliative sedation for existential suffering: a systematic review of argument-based ethics literature. J Pain Symptom Manage. 2018;55:1577–90.PubMedGoogle Scholar
  31. 31.
    Scherrens AL, Roelands M, Van den Block L, Deforche B, Deliens L, Cohen J. What influences intentions to request physician-assisted euthanasia or continuous deep sedation? Death Stud. 2018;42:491–7.PubMedGoogle Scholar
  32. 32.
    Bruce A, Boston P. Relieving existential suffering through palliative sedation: discussion of an uneasy practice. J Adv Nurs. 2011;67:2732–40.PubMedGoogle Scholar
  33. 33.
    Schuman-Olivier Z, Brendel DH, Forstein M, Price BH. The use of palliative sedation for existential distress: a psychiatric perspective. Harv Rev Psychiatry. 2008;16:339–51.PubMedGoogle Scholar
  34. 34.
    Harris DG, Noble SI. Management of terminal hemorrhage in patients with advanced cancer: a systematic literature review. J Pain Symptom Manage. 2009;38:913–27.PubMedGoogle Scholar
  35. 35.
    Gonçalves F, Almeida A, Teixeira S, Pereira S, Edra N. A protocol for the acute control of agitation in palliative care: a preliminary report. Am J Hosp Palliat Care. 2012;29:522–4.PubMedGoogle Scholar
  36. 36.
    Morita T, Imai K, Yokomichi N, Mori M, Kizawa Y, Tsuneto S. Continuous deep sedation: a proposal for performing more rigorous empirical research. J Pain Symptom Manage. 2017;53:146–52.PubMedGoogle Scholar
  37. 37.
    Imai K, Morita T, Yokomichi N, Mori M, Naito AS, Tsukuura H, et al. Efficacy of two types of palliative sedation therapy defined using intervention protocols: proportional vs. deep sedation. Support Care Cancer. 2018;26:1763–71.PubMedGoogle Scholar
  38. 38.
    Laryionava K, Pfeil TA, Dietrich M, Reiter-Theil S, Hiddemann W, Winkler EC. The second patient? Family members of cancer patients and their role in end-of-life decision making. BMC Palliat Care. 2018;17:29.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Maiser S, Estrada-Stephen K, Sahr N, Gully J, Marks S. A survey of hospice and palliative care clinicians’ experiences and attitudes regarding the use of palliative sedation. J Palliat Med. 2017;20:915–21.PubMedGoogle Scholar
  40. 40.
    Mercadante S, Masedu F, Mercadante A, Marinangeli F, Aielli F. Attitudes of palliative home care physicians towards palliative sedation at home in Italy. Support Care Cancer. 2017;25:1615–20.PubMedGoogle Scholar
  41. 41.
    Mercadante S, Porzio G, Valle A, Fusco F, Aielli F, Costanzo V. Home Care Italy Group Palliative sedation in patients with advanced cancer followed at home: a systematic review. J Pain Symptom Manage. 2011;41:754–60.PubMedGoogle Scholar
  42. 42.
    Mercadante S, Porzio G, Valle A, Aielli F, Casuccio A. Home Care-Italy Group Palliative sedation in patients with advanced cancer followed at home: a prospective study. J Pain Symptom Manage. 2014;47:860–6.PubMedGoogle Scholar
  43. 43.
    Pype P, Teuwen I, Mertens F, Sercu M, De Sutter A. Suboptimal palliative sedation in primary care: an exploration. Acta Clin Belg. 2018;73:21–8.PubMedGoogle Scholar
  44. 44.
    Caraceni A, Speranza R, Spoldi E, Ambroset CS, Canestrari S, Marinari M, et al. Italian Society of Palliative Care Study Group on Palliative Sedation. Palliative sedation in terminal cancer patients admitted to hospice or home care programs: does the setting matter? Results from a national multicenter observational study in adult cancer patients. J Pain Symptom Manage. 2018;13:30133–7.Google Scholar
  45. 45.
    Arevalo JJ, Geijteman ECT, Huisman BAA, Dees MK, Zuurmond WWA, van Zuylen L, et al. Medication use in the last days of life in hospital, hospice, and home settings in the Netherlands. J Palliat Med. 2018;21:149–55.PubMedGoogle Scholar
  46. 46.
    Smedbäck J, Öhlén J, Årestedt K, Alvariza A, Fürst CJ, Håkanson C. Palliative care during the final week of life of older people in nursing homes: a register-based study. Palliat Support Care. 2017;15:417–24.PubMedGoogle Scholar
  47. 47.
    Andersson S, Årestedt K, Lindqvist O, Fürst CJ, Brännström M. Factors associated with symptom relief in end-of-life care in residential care homes: a national register-based study. J Pain Symptom Manage. 2018;55:1304–12.PubMedGoogle Scholar
  48. 48.
    Eun Y, Hong IW, Bruera E, Kang JH. Qualitative study on the perceptions of terminally ill cancer patients and their family members regarding end-of-life experiences focusing on palliative sedation. J Pain Symptom Manage. 2017;53:1010–6.PubMedGoogle Scholar
  49. 49.
    Trees AR, Ohs JE, Murray MC. Family communication about end-of-life decisions and the enactment of the decision maker role. BehavSci (Basel). 2017;7:pii E36.Google Scholar
  50. 50.
    Lövgren M, Sveen J, Nyberg T, EilegårdWallin A, Prigerson HG, Steineck G, et al. Care at end of life influences grief: a nationwide long-term follow-up among young adults who lost a brother or sister to childhood cancer. J Palliat Med. 2018;21:156–62.PubMedGoogle Scholar
  51. 51.
    Shen HS, Chen SY, Cheung DST, Wang SY, Jung Jae L, Lin CC. Differential family experience of palliative sedation therapy in specialised palliative or critical careunits. J Pain Symptom Manage. 2018;55:1531–9.PubMedGoogle Scholar
  52. 52.
    Giles A, Sykes N. To explore the relationship between the use of midazolam and cessation of oral intake in the terminal phase of hospice inpatients: a retrospective case note review: does midazolam affect oral intake in the dying? Palliat Med. 2017;31:89–92.PubMedGoogle Scholar
  53. 53.
    Dev R, Dalal S, Bruera E. Is there a role for parenteral nutrition or hydration at the end of life? Curr Opin Support Palliat Care. 2012;6:365–70.PubMedGoogle Scholar
  54. 54.
    Franken LG, de Winter BC, van Esch HJ, van Zuylen L, Baar FP, Tibboel D, et al. Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. Expert Opin Drug Metab Toxicol. 2016;12:669–80.PubMedGoogle Scholar
  55. 55.
    Franken LG, Masman AD, de Winter BC, Koch BC, Baar FP, Tibboel D, et al. Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill adult patients. Clin Pharmacokinet. 2016;55:697–709.PubMedGoogle Scholar
  56. 56.
    Franken LG, de Winter BCM, Masman AD, van Dijk M, Baar FPM, Tibboel D, et al. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br J Clin Pharmacol. 2018;84:320–30.PubMedGoogle Scholar
  57. 57.
    Dickman A, Bickerstaff M, Jackson R, Schneider J, Mason S, Ellershaw J. Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability. BMC Palliat Care. 2017;16:22.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Morita T, Chinone Y, Ikenaga M, et al. Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage. 2005;30:320–8.PubMedGoogle Scholar
  59. 59.
    Ferrari L, Caraceni A. Pharmacology of sedation. In: Grassi L, Riba M, editors. Psychopharmacology in oncology and palliative care. Berlin: Springer-Verlag; 2014. p. 375.Google Scholar
  60. 60.
    Franken LG, Masman AD, de Winter BC, Baar FP, Tibboel D, van Gelder T, et al. Hypoalbuminemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect? Br J Clin Pharmacol. 2017;83:1701–12.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Cheng C, Roemer-Becuwe C, Pereira J. When midazolam fails. J Symptom Manage. 2002;23:256–65.Google Scholar
  62. 62.
    Bodnar J. A review of agents for palliative sedation/continuous deep sedation: pharmacology and practical applications. J Pain Palliat Care Pharmacother. 2017;31:16–37.PubMedGoogle Scholar
  63. 63.
    Beller EM, van Driel ML, McGregor L, Truong S, Mitchell G. Palliative pharmacological sedation for terminally ill adults. Cochrane Database Syst Rev. 2015;1:CD010206.PubMedGoogle Scholar
  64. 64.
    Hui D, Frisbee-Hume S, Wilson A, Dibaj SS, Nguyen T, De La Cruz M, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA. 2017;318:1047–56.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Doyle D, Hanks GWC, MacDonald N, editors. Oxford textbook of palliative medicine. 1st ed. Oxford: Oxford University Press; 1993.Google Scholar
  66. 66.
    Franken LG, Mathot RAA, Masman AD, Baar FPM, Tibboel D, van Gelder T, et al. Population pharmacokinetics of haloperidol in terminally ill adult patients. Eur J Clin Pharmacol. 2017;73:1271–7.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med. 2017;177:34–42.PubMedGoogle Scholar
  68. 68.
    Lee J, Holbrook A. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. Ann Intern Med. 2017;166:JC32.PubMedGoogle Scholar
  69. 69.
    Shrikant Kulkarni N. Antipsychotics worsen symptoms in patients with delirium who receive palliative care. Am Fam Physician. 2017;95:396B.Google Scholar
  70. 70.
    Boettger S, Jenewein J. Placebo might be superior to antipsychotics in management of delirium in the palliative care setting. Evid Based Med. 2017;22:152–3.PubMedGoogle Scholar
  71. 71.
    Kayhart B, Lapid MI, Nelson S, Cunningham JL, Thompson VH, Leung JG. A lack of systemic absorption following the repeated application of topical quetiapine in healthy adults. Am J HospPalliat Care. 2018;35:1076–80.Google Scholar
  72. 72.
    Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333–40.PubMedGoogle Scholar
  73. 73.
    Elsayem A, Bush SH, Munsell MF, Curry E 3rd, Calderon BB, Paraskevopoulos T, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manage. 2010;40:774–82.PubMedGoogle Scholar
  74. 74.
    Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12:655–62.PubMedGoogle Scholar
  75. 75.
    Prommer E. Aripiprazole. Am J Hosp Palliat Care. 2017;34:180–5.PubMedGoogle Scholar
  76. 76.
    Kirino E. Use of aripiprazole for delirium in the elderly: a short review. Psychogeriatrics. 2015;15:75–84.PubMedGoogle Scholar
  77. 77.
    Hui D, Dev R, Bruera E. Neuroleptics in the management of delirium in patients with advanced cancer. Curr Opin Support Palliat Care. 2016;10:316–23.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Bascom PB, Bordley JL, Lawton AJ. High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. Am J Hosp Palliat Care. 2014;31:808–11.PubMedGoogle Scholar
  79. 79.
    Chen A, Loquias EJ, Roshan R, Levene R, Zelhof R, Hickey T, et al. Safe use of subcutaneous diphenhydramine in the Inpatient Hospice Unit. Am J Hosp Palliat Care. 2017;34:954–7.PubMedGoogle Scholar
  80. 80.
    Prommer E. Dexmedetomidine: does it have potential in palliative medicine? Am J Hosp Palliat Care. 2011;28:276–83.PubMedGoogle Scholar
  81. 81.
    Burns J, Jackson K, Sheehy KA, Finkel JC, Quezado ZM. The use of dexmedetomidine in pediatric palliative care: a preliminary study. J Palliat Med. 2017;20:779–83.PubMedGoogle Scholar
  82. 82.
    Ciais JF, Tremellat F, Castelli-Prieto M, Jestin C. Sedation by propofol for painful care procedures at the end of life: a pilot study. PROPOPAL 1. J Palliat Med. 2017;20:282–4.PubMedGoogle Scholar
  83. 83.
    Covarrubias-Gómez A, LópezCollada-Estrada M. Propofol-based palliative sedation to treat antipsychotic-resistant agitated delirium. J Pain Palliat Care Pharmacother. 2017;16:1–5.Google Scholar
  84. 84.
    Sutherland AE, Curtin J, Bradley V, Bush O, Presswood M, Hedges V, et al. Subcutaneous levetiracetam for the management of seizures at the end of life. BMJ Support Palliat Care. 2018;8:129–35.PubMedGoogle Scholar
  85. 85.
    Carter MJ, Gibbins J, Senior-Smith G, Thomas S, Guest P, Forbes K. Ketamine: does it have a role in palliative sedation? J Pain Symptom Manage. 2008;36:e1–3.PubMedGoogle Scholar
  86. 86.
    Maeda I, Morita T, Yamaguchi T, Inoue S, Ikenaga M, Matsumoto Y, et al. Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol. 2016;17:115–22.PubMedGoogle Scholar
  87. 87.
    Golčić M, Dobrila-Dintinjana R, Golčić G, Čubranić A. The impact of combined use of opioids, antipsychotics and anxiolytics on survival in the hospice setting. J Pain Symptom Manage. 2018;55:22–30.PubMedGoogle Scholar
  88. 88.
    De Lima L, Wenk R, Pettus K, Radbruch L. No occultation in the international association for hospice and palliative care position statement on palliative care and assisted suicide. J Palliat Med. 2017;20:1309–10.PubMedGoogle Scholar
  89. 89.
    Radbruch L, Leget C, Bahr P, Müller-Busch C, Ellershaw J, de Conno F, et al. Board members of EAPC. Euthanasia and physician-assisted suicide: a white paper from the European Association for Palliative Care. Palliat Med. 2016;30:104–16.PubMedGoogle Scholar
  90. 90.
    Koff G, Vaid U, Len E, Crawford A, Oxman DA. Differences in utilization of life support and end-of-life care for medical icu patients with versus without cancer. Crit Care Med. 2017;45:e379–83.PubMedGoogle Scholar
  91. 91.
    Leung D, Angus JE, Sinuff T, Bavly S, Rose L. Transitions to end-of-life care for patients with chronic critical illness: a meta-synthesis. Am J Hosp Palliat Care. 2017;34:729–36.PubMedGoogle Scholar
  92. 92.
    Axelsson L, Alvariza A, Lindberg J, Öhlén J, Håkanson C, Reimertz H, et al. Unmet palliative care needs among patients with end-stage kidney disease: a national registry study about the last week of life. J Pain Symptom Manage. 2018;55:236–44.PubMedGoogle Scholar
  93. 93.
    Årestedt K, Alvariza A, Boman K, Öhlén J, Goliath I, Håkanson C, et al. Symptom relief and palliative care during the last week of life among patients with heart failure: a national register study. J Palliat Med. 2018;21:361–7.PubMedGoogle Scholar
  94. 94.
    Bergman YS, Bodner E, Shrira A. Subjective nearness to death and end-of-life anxieties: the moderating role of ageism. Aging Ment Health. 2018;22:678–85.PubMedGoogle Scholar
  95. 95.
    Johnson LM, Frader J, Wolfe J, Baker JN, Anghelescu DL, et al. Palliative sedation with propofol for an adolescent with a DNR order. Pediatrics. 2017;140:e20170487.PubMedGoogle Scholar
  96. 96.
    Suttle ML, Jenkins TL, Tamburro RF. End-of-Life and bereavement care in pediatric intensive care units. Pediatr Clin North Am. 2017;64:1167–83.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Ziegler S, Merker H, Schmid M, Puhan MA. The impact of the inpatient practice of continuous deep sedation until death on healthcare professionals emotional well being: a systematic review. BMC Palliat Care. 2017;16:30.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Schildmann E, Pörnbacher S, Kalies H, Bausewein C. Palliative sedation? A retrospective cohort study on the use and labelling of continuously administered sedatives on a palliative care unit. Palliat Med. 2018;32:1189–97.PubMedGoogle Scholar
  99. 99.
    Rietjens JA, van Delden JJ, van der Heide A. Palliative sedation: the end of heated debate? Palliat Med. 2018;269216318762708. (Epub ahead of print).Google Scholar
  100. 100.
    Maltoni M, Scarpi E, Dall’Agata M, Zagonel V, Bertè R, Ferrari D, et al. Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. Eur J Cancer. 2016;65:61–8.PubMedGoogle Scholar
  101. 101.
    Maltoni M, Scarpi E, Dall’Agata M, Schiavon S, Biasini C, Codecà C, et al. Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer. 2016;69:110–8.PubMedGoogle Scholar
  102. 102.
    Hoerger M, Greer JA, Jackson VA, Park ER, Pirl WF, El-Jawahri A, et al. Defining the elements of early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care. J ClinOncol. 2018;36:1096–102.Google Scholar
  103. 103.
    Davies EA. Why we need more poetry in palliative care. BMJ Support Palliat Care. 2018;8:266–70.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Ferdinando Garetto
    • 1
  • Ferdinando Cancelli
    • 2
  • Romina Rossi
    • 3
  • Marco Maltoni
    • 3
  1. 1.Medical Oncology UnitPresidio Humanitas GradenigoTurinItaly
  2. 2.Fondazione FARO OnlusTurinItaly
  3. 3.Palliative Care UnitIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMeldolaItaly

Personalised recommendations